The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
In a special Good Day PA segment, an interviewer connected with Dr. Gary Kirman on the importance of optimal care when it comes to eye health, particularly with regard to AMD.
Testing dark adaptation speed for every patient over 50 allows eye care professionals prioritize both patients and practice. By Tammy Tully, OD.
Victoria Dzurinko, OD, MBA, FAAO, discusses the opportunity available to improve both patient outcomes and practice bottom lines by integrating dark adaptation testing in the identification and management of AMD.